Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Payables (2022 - 2026)

Pediatrix Medical (MD) has disclosed Payables for 11 consecutive years, with $419.5 million as the latest value for Q4 2025.

  • Quarterly Payables rose 5.23% to $419.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $419.5 million through Dec 2025, up 5.23% year-over-year, with the annual reading at $419.5 million for FY2025, 5.23% up from the prior year.
  • Payables for Q4 2025 was $419.5 million at Pediatrix Medical, up from $38.7 million in the prior quarter.
  • The five-year high for Payables was $419.5 million in Q4 2025, with the low at $34.6 million in Q4 2023.
  • Average Payables over 4 years is $214.7 million, with a median of $277.7 million recorded in 2023.
  • The sharpest move saw Payables tumbled 90.76% in 2023, then soared 1052.68% in 2024.
  • Over 4 years, Payables stood at $374.2 million in 2022, then crashed by 90.76% to $34.6 million in 2023, then skyrocketed by 1052.68% to $398.7 million in 2024, then increased by 5.23% to $419.5 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $419.5 million, $38.7 million, and $42.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.